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Abstract
Background:  Neurovirulent Venezuelan equine encephalitis virus (VEEV) causes lethal
encephalitis in equines and is transmitted to humans by mosquitoes. VEEV is highly infectious when
transmitted by aerosol and has been developed as a bio-warfare agent, making it an important
pathogen to study from a military and civilian standpoint. Molecular mechanisms of VEE
pathogenesis are poorly understood. To study these, the gene expression profile of VEEV infected
mouse brains was investigated. Changes in gene expression were correlated with histological
changes in the brain. In addition, a molecular framework of changes in gene expression associated
with progression of the disease was studied.
Results: Our results demonstrate that genes related to important immune pathways such as
antigen presentation, inflammation, apoptosis and response to virus (Cxcl10, CxCl11, Ccl5, Ifr7, Ifi27
Oas1b, Fcerg1,Mif, Clusterin and MHC class II) were upregulated as a result of virus infection. The
number of over-expressed genes (>1.5-fold level) increased as the disease progressed (from 197,
296, 400, to 1086 at 24, 48, 72 and 96 hours post infection, respectively).
Conclusion: Identification of differentially expressed genes in brain will help in the understanding
of VEEV-induced pathogenesis and selection of biomarkers for diagnosis and targeted therapy of
VEEV-induced neurodegeneration.
Background
Venezuelan equine encephalitis virus (VEEV) is an
alphavirus in the family Togaviridae. It causes a highly vir-
ulent central nervous system (CNS) disease in horses and
other equines and is transmitted to humans by mosqui-
toes. Outbreaks of VEEV have been reported at intervals of
2 to 10 years in South and Central America and in the
Texas region of North America, which has resulted in
VEEV being included on the list of emerging pathogens
[1]. VEEV has also been developed as a bio-warfare agent,
making its use more likely than other non-weaponized
agents in the event that a bio-weapon or bio-terrorism
agent is used [2]. There is no specific treatment available
for VEEV. A vaccine for prophylaxis against VEEV is under
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investigational new drug status and is given to personnel
at risk of occupational exposure to VEEV. This vaccine has
several limitations and has not been licensed by the FDA.
VEEV infection in mice induces the bi-phasic disease
observed in equines and lethal human infections (~0.5%)
thus making it a good model to study VEEV pathogenesis
[3,4]. VEEV spreads from the site of inoculation through
the locally draining lymph nodes, causes viremia, and dis-
seminates to other lymphoid organs [5]. Viremia is fol-
lowed by a CNS phase of disease [6-8]. VEEV enters into
the CNS primarily through the olfactory neuroepithe-
lium, via brain capillary endothelial cells and the trigemi-
nal nerve [7,9]. In the CNS, VEEV infects neurons and glial
cells and causes subsequent cellular degeneration. Infec-
tion with VEEV results in neuronal cell death, active gliosis
and an intense inflammatory response characterized by
perivascular and interstitial mononuclear cell infiltration
[4,5,10-13]. However, in another subset of dying neurons
associated with astrogliosis, no VEEV antigen can be
found, indicating an alternate, indirect mechanism of
neuronal degeneration [11,13].
As the mechanism(s) underlying the inflammatory and
immune response to VEEV infection in brain and subse-
quent neurodegenration are poorly understood, it is
important to characterize the underlying cellular and
molecular pathways. To fulfill this objective we used the
virulent neuroinvasive strain, V3000, of VEEV. Gene
expression changes in VEEV-infected mouse brain were
studied using microarrays containing 16,463 oligonucle-
otides, representing 15,000 genes. We demonstrate that
with the progression of disease both the total number of
genes and fold expression of numerous genes increased.
Many of the changes were associated with important
immune pathways such as antigen presentation, inflam-
mation, apoptosis and viral response. Gene expression
changes were validated by RT-PCR. Pathologic changes in
the brain were documented by H&E (hematoxylin and
eosin) and immunohistochemistry (IHC).
Results
Survival of animals post VEEV infection
Mice began showing roughening of fur and hunched back
at day 2 post infection. By day 4, animals were lethargic
and at least one mouse had hind limb paralysis. One ani-
mal died on day 5 post infection and all other animals
showed little or no movement. All the mice died by day 9
post infection. Mortality was 100% with mean survival
time of 6.6 days. Animal mortality is documented in Table
1.
Histopathology and immunohistochemistry for VEEV 
antigen
VEEV antigen-specific staining showed the presence of
viral antigen within neurons and glial cells in the olfactory
and prefrontal areas of the brain at 48 hr post infection.
Many more VEEV infected neurons and glial cells were
present throughout the brain at 72 hr post infection. VEEV
antigen was present throughout the brain at 96 hr post
infection and the degree of inflammation corresponded to
the density of virus infected cells. Inflammation started
with perivascular cuffing and localizaton to the meninges
at 48 hr post infection. At 72 hr post infection, inflamma-
tion was observed in the olfactory and frontal area of the
brain. By 96 hr post-infection inflammation was extensive
and had spread throughout the brain (Fig 1).
Gene expression analysis
Microarrays were performed using RNA extracted from
VEEV-infected mouse brain at 24 hr, 48 hr, 72 hr and 96
hr post infection and gene expression profile were com-
pared with RNA extracted from saline infected control
mice at similar time points. All the biological replicates
(duplicates for each time point) shared significant homol-
ogy in gene expression (correlation coefficient ≥ 0.80).
Mean fold-expression of biological replicates ≥ 1.5 fold
over control was determined to be significant. As shown
in Table 2, the number of genes upregulated in brain
increased as disease progressed (Fig 1). At 96 hr post infec-
Table 1: Progression of disease and mortality in VEEV infected mice.
Disease Progression Day(s) Post Infection
01234 5 6 7 8 9
R o u g h e n i n g  o f  F u r 00599 8 5 1 1 -
H u n c h e d  P o s t u r e / L e t h a r g i c / S h i v e r i n g 00009 8 5 1 1 -
H i n d  L i m b  P a r a l y s i s 00001 8 5 1 1 -
D e a t h 00000 1 3 4 0 1
Total died/Total No. 0/9 0/9 0/9 0/9 0/9 1/9 4/9 8/9 8/9 9/9
%  M o r t a l i t y 00000 1 1 . 1 4 4 . 4 8 8 . 8 8 8 . 8 1 0 0
MST (Day) 6.66
Mice were infected with 1000 pfu of V3000 in left rear foot pad at day 0 and were monitored for the clinical symptoms of disease thereafter. All the 
animals exhibited hind limb paralysis, a hallmark of VEEV infection and succumbed to disease by day 9 post infection. Mortality was 100% with a 
mean survival time of 6.6 days.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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Evidence of VEEV infection in mouse brain Figure 1
Evidence of VEEV infection in mouse brain. Mouse brains at various time points after VEEV infection were analyzed by 
H&E and IHC staining. VEEV appeared in brain at 48 hr post infection (indicated by arrows), which was accompanied by the ini-
tiation of inflammation in brain as evident by vessel thickening and endothelial cuffing. At 72 hr post infection VEEV antigen can 
be detected throughout the mid-brain. Inflammation was evidenced by increased endothelial cuffing and neutrophil infiltration 
(indicated by arrows). Inflammation was extensive throughout the brain along with increased VEEV antigen in brain at 96 hr 
post infection.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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tion the maximum numbers of total genes were upregu-
lated at ≥ 1.5 fold levels in mouse brain.
To analyze similarities and difference in gene expression
between brains at different time points, hierarchical clus-
tering analysis was done for all genes at the four time
points. Genes which showed a distinct pattern of over-
expression with the time of VEEV infection are shown in
Fig 2. All genes were grouped in two clusters. The first clus-
ter contained genes upregulated at 24 hr and 48 hr,
whereas the second cluster contained genes upregulated at
72 hr and 96 hr post infection. This analysis clearly distin-
guished the changes in the gene expression profile with
the progression of VEEV infection. Some genes related to
the inflammatory response, such as Cxcl10, Clu and anti-
gen presentation, such as B2m,  Fcer1g  showed over-
expression only at 72 and 96 hr post infection (Fig 2).
Functional analysis of over-expressed genes was per-
formed using the GOFFA (gene ontology for functional
analysis) library of the Arraytrack software. Genes belong-
ing to various biological processes were grouped together.
Based on these analyses, a majority of genes (164, 251,
759, 928) were identified to play a role in different biolog-
ical processes at 24 hr, 48 hr, 72 hr, and 96 hr post infec-
tion, respectively. These genes were further categorized by
the various functions that may play an important role in
VEEV pathogenesis (Fig 3) as follows:
i) Virus response genes
It has been shown that interferon and interferon-induci-
ble genes play an important role in the immune response
towards viral pathogens. Consistent with this informa-
tion, several interferon-inducible genes were upregulated
(Table 3) in present study. These include Ifi27, Ifih1, Irf7
and Oas1b which were upregulated at 72 hr and 96 hr post
infection except Becn1 that was over-expressed only at 72
hr post infection, and Spn which was over-expressed at all
time points.
ii) Inflammatory response genes
Inflammation constitutes an important part of the
immune response towards the invading pathogen. In
VEEV infection, inflammation in brain is implicated in
the secondary neuronal damage leading to morbidity and
mortality. Several genes related to the inflammatory
response were upregulated in the brain following VEEV
infection, mostly at 72 and 96 hr post infection (Table 3).
Most importantly, chemokine genes e.g., Cxcl9, Cxcl10,
Cxcl11, Cxcl13, Ccl3, Ccl5 and Ccl12 that exert a chemo-
tactic signal for the immune cell migration to the site of
the injury were upregulated at 72 and 96 hr post infection.
These gene expression correlates with the increased neu-
trophil infiltration in brain and blood brain barrier (BBB)
compromise (Fig 1). In addition inflammatory genes e.g.,
Fcer1g, and Mif were also over-expressed at 72 and 96 hr
post infection. (Table 3)
iii) Genes involved in antigen presentation (AP)
Resident glial cells of the brain are known to act as antigen
presenting cells and constitute an important part of the
immune response against a virus pathogen. Several major
histocompatibility complex (MHC) class II genes e.g., H2-
D1, H2-D4 H2-Q7 and H2-T23 were upregulated at 72 hr
and 96 hr post infection, concomitant with VEEV antigen
appearance in the brain. MHC class I receptors such as
Cd1d1, B2m and Ap3d1 were also upregulated at 96 hr
post infection. (Table 3)
iv) Apoptotic gene expression
Apoptotic neurons were seen in the VEEV-infected mouse
brain in regions associated with VEEV antigen and the
regions of gliosis that are free of VEEV antigen. Several
apoptotic genes such as caspase recruitment domain
(Card)14, fas apoptotic inhibitory molecule (Faim)2,
Apoptosis-associated tyrosine kinase (Aatk), eukaryotic
translation initiation factor 5 (Eif5a) and myeloid cell
leukemia sequence 1 (Mcl1) were upregulated at 72 hr
and 96 hr post infection (Fig 3). Few genes, like amyloid
beta (A4) precursor protein (App), bcl2/adenovirus e1b
interacting protein 3-like (Bnip3l), baculoviral IAP repeat-
containing 6 (Birc6) and Spn were upregulated through-
out the study and few others such as amyloid beta (A4)
precursor-like protein 1 (Aplp1), Clusterin (Clu), integral
membrane protein 2B (Itm2b), and valosin containing
protein (Vcp), were upregulated as early as 48 hr post
infection (Table 4).
Apart from over-expressed genes, few genes were down-
regulated (≤2 fold) at all time points. Those genes are
Table 2: Total Genes Upregulated in VEEV Infected Mice brain.
Time, Hour(s) pi > 5.0 folds > 3.0–5.0 folds ≥ 1.5–3.0 folds Total genes over-expressed
24 6 18 183 207
48 3 27 292 322
72 53 148 212 413
96 33 129 960 1122
Total RNA extracted from VEEV infected brain was analyzed by microarray as described in methods. Gene's upregulated ≥1.5 folds were 
considered. Number of genes over expressed increased as the disease progressed with maximum genes over expressed at 96 hr post infection.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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listed in supplementary table 1. As expected, the func-
tional analysis showed genes related to several cellular
physiological processes such as cell transport (Atp5j2,
Slc18a2, Actr6, Timm8b) cell cycle/division (Cetn3), cellu-
lar metabolism (Zfp99, Rpl37a, Pigf, Snrpe, Rps26, Rps12,
Rpl39, Rpl26, Rpl30, Cox7c, Ndufc1, Mrps33 and Ppia) and
other cellular processes (stmn3, Pvalb, Pcp4, Usmg5) were
down-regulated in VEEV infection.
Confirmation of gene expression
Randomly selected genes identified in the microarrays
were analyzed by semi-quantitative RT-PCR analysis in 3–
Hierarchical clustering of gene expression in mouse brain after VEEV infection Figure 2
Hierarchical clustering of gene expression in mouse brain after VEEV infection. All over-expressed genes were 
clustered; however, a snap shot of selected genes is shown due to space limitation. Genes that are marked with arrows are 
over expressed ≥ 2.0 fold at 72 and 96 hr post infection. Color indicates the relative expression level of each gene in VEEV 
infected brain over saline treated control mouse brain, with red indicating higher expression, grey indicating absence of expres-
sion and darker red color indicating over expression but at a lower level.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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4 biological replicates. Specific amplification was con-
firmed by sequencing PCR products as described in mate-
rials and methods (data not shown). As shown in Fig 4,
the expression of genes Oas1b, Fcre1g and Clu was up-reg-
ulated in mouse brain infected with VEEV. Although RT-
PCR analysis was not quantitative, consistent with micro-
array analysis, gene expression of Fcer1g, Oas1b and Clu
was higher at 48, 72 and 96 hr post infection as compared
to saline control and 24 hr post infection (Fig 4)
Discussion
The proximal cause of death following VEEV infection is
attributed to the host immune response to replicating
virus resulting in lethal encephalitis [8]. Therefore, it is
important to study the kinetics of changes in gene expres-
sion in the brain of the VEEV infected host to understand
the resulting immune response and to identify potential
therapeutic targets and markers for treatment of VEEV
infection. In the present study, total RNA isolated from
mouse brain was used. This consisted of RNA from all the
cell types present in the VEEV infected mouse brain. The
goal of the study was to characterize the overall molecular
frame work of gene expression in the brain. In this way,
the changes in gene expression could be directly corre-
lated with the tissue pathology. Since different cell types,
individually, may respond differently to VEEV infection it
is imperative to study the overall gene expression patterns
during disease progression in tissue containing all the rel-
evant cells.
Consistent with the histopathological changes, microar-
ray analysis showed over-expression of the genes involved
in the various immune responses towards the pathogen.
For example Oas1b, Ifi27, Ifih1 and Irf7 genes were up-reg-
ulated at 72 and 96 hr post infection. Elevated level of
Oas1b has been shown to inhibit West Nile virus (WNV)
replication by reducing the positive strand viral RNA level
in cells [14]. Since VEEV is a positive single strand RNA
virus, increased Oas1b levels may also potentially inhibit
VEEV replication. The anti-VEEV activity of interferon
(IFN) and interferon regulatory factor (IRF) is also well
established [15,16]. IFN  α/β  knockout mice showed
increased and early spread of VEEV into brain, and IRF2
knockout mice showed increased susceptibility to other-
wise avirulent strains of VEEV [17].
The ability of microglia, the brain's resident macrophage,
to present antigen associated with MHC class II to T cells,
allows these normally quiescent cells to play a critical role
in shaping the outcome of many neurological diseases
[18,19]. Activated glial cells are observed in the brains of
VEEV-infected mice [10,11]. Consistent with these
reported observations, upregulated MHC class II loci
genes such as H2-D1, H2-D4 H2-Q7 and H2-T23 in the
present study may reflect the activated state of glial cells in
the brain of VEEV infected mice. Several molecules associ-
ated with MHC-I-mediated presentation such as B2m,
Fcerg1 and Cd1d1 were also upregulated in our study. Beta
2 microglobulin (B2m) was also upregulated in acquired
Analysis of molecular pathways in VEEV infected brain Figure 3
Analysis of molecular pathways in VEEV infected brain. Number of genes involved in various pathways of biological 
processes was analyzed by GOFFA Library of Arraytrack software. Genes involved in the various biological processes 
increased with the progress of the disease.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
Page 7 of 12
(page number not for citation purposes)
immunodeficiency syndrome encephalitis and JC virus
infection of the CNS [20,21]. Fc-receptors are important
in antigen processing/presentation of myelin proteins
during the autoimmune response in the CNS [22] and
contribute to inflammatory damage in the CNS. Cd1d1
plays a critical role in the regulation of cytokine produc-
tion after an acute virus infection [23]. Thus, in the current
study, VEEV infection in mice induces a similar host
immune response as observed with other viruses.
VEEV infection of the CNS has been shown to result in
neurodegeneration, perivascular cuffing with infiltrating
lymphocytes, gliosis, cerebral edema and apoptotic neu-
rons associated with astrogliosis in the regions of the
brain which is free of VEEV antigen [10]. Therefore, it is
not clear whether VEEV is directly or indirectly involved
with these changes. To understand this phenomenon we
investigated whether the expression of chemokines,
cytokines and other inflammatory genes is altered in
VEEV infected brain. Interestingly, chemokines such as
Cxcl9, Cxcl10, Cxcl11, Cxcl13, Ccl3, Ccl5 and Ccl12, Fc-
receptor such as Fcer1g, and Mif genes were upregulated.
These chemokines may contribute to the influx of neu-
trophils and lymphocytes as observed in the brain (Fig 2)
and the severity of the encephalitis during VEEV infection.
Fc-receptor,Fcerg1 may contribute in VEEV antigen pres-
entation to T cells and induction of inflammatory
cytokines. The cytokine expression at the site of inflam-
mation is suggested to be the outcome of interaction of
glucocorticoids and macrophage migration inhibitory fac-
tor (Mif) [24-26]. Though over-expressed in the microar-
ray, only a marginal increase in expression of Mif  was
Table 3: Genes involved in virus response, inflammatory response and antigen presentation
UniGene ID Functional Grouping (Gene) Upregulation (fold change) (Hours post infection)
24 48 72 96
Virus Response and Inflammation
Mm.136224 Interferon induced with helicase C domain 1 (Ifih1) NE 3.59/- 5.21 ± 1.05 4.18 ± 0.31
Mm.3233 Interferon regulatory factor 7 (Irf7) NE NE 4.31 ± 1.51 2.01 ± 0.08
Mm.271275 Interferon, alpha-inducible protein 27 (Ifi27) NE NE 4.79 ± 0.67 6.62 ± 0.32
Mm.233471 2'-5' oligoadenylate synthetase 1B (Oas1b) NE 1.89/- 5.12 ± 0.04 2.32 ± 0.08
Mm.867 Chemokine (C-C motif) ligand 12 (Ccl12) 5.03 ± 1.86 4.63/- 7.87 ± 0.54 4.70 ± 0.36
Mm.131723 Chemokine (C-X-C motif) ligand 11 (Cxcl11) NE 8.76/- 17.02 ± 5.19 13.68 ± 5.51
Mm.877 Chemokine (C-X-C motif) ligand 10 (Cxcl10) NE 7.49/- 15.45 ± 0.67 8.69 ± 0.37
Mm.284248 Chemokine (C-C motif) ligand 5 (Ccl5) NE NE 4.27 ± 1.27 3.56 ± 0.66
Mm.1282 Chemokine (C-C motif) ligand 3 (Ccl3) NE NE 2.26/1.83 2.05 ± 0.21
Mm.10116 Chemokine (C-X-C motif) ligand 13 (Cxcl13) NE NE 2.06 ± 0.41 1.73/-
Mm.766 Chemokine (C-X-C motif) ligand 9 (Cxcl9) NE NE 3.99 ± 1.62 1.85 ± 0.14
Mm.22673 Fc receptor, IgE, high affinity I, gamma polypeptide (Fcer1g) NE NE 3.66 ± 0.29 3.38 ± 0.63
Mm.5419 Interleukin 17 (Il17) NE NE NE 2.06 ± 0.33
Mm.2326 Macrophage migration inhibitory factor (Mif) NE 1.08 ± 0.17 2.25 ± 0.53 2.06 ± 0.07
Mm.24163 PYD and CARD domain containing (Pycard) NE NE 1.81 ± 0.165 1.52 ± 0.31
Mm.200608 Clusterin (Clu) NE 1.74 ± 0.13 4.03 ± 1.54 2.45 ± 0.37
Mm.283714 Sialophorin (Spn) 1.93 ± 0.14 2.50 ± 0.19 2.87 ± 1.63 2.25 ± 0.24
Antigen Presentation
Mm.209294 Adaptor-related protein complex 3, delta 1 subunit (Ap3d1) 1.33 ± 0.83 NE 2.17 ± 0.35 1.69 ± 0.01
Mm.163 Beta-2 microglobulin (B2m) NE NE 10.39 ± 0.32 6.07 ± 0.25
Mm.1894 CD1d1 antigen (Cd1d1) NE NE NE 1.56 ± 0.01
Mm.22673 Fc receptor, IgE, high affinity I, gamma polypeptide (Fcer1g) NE NE 3.66 ± 0.29 3.38 ± 0.63
Mm.33263 Histocompatibility 2, D region locus 1 (H2-D1) NE NE 4.88 ± 0.12 9.04 ± 1.15
Mm.387141 Histocompatibility 2, D region locus 4 (H2-D4) NE NE 8.92 ± 7.66 9.42 ± 1.34
Mm.35016 Histocompatibility 2, T region locus 23 (H2-T23) NE NE 4.72 ± 0.89 3.15 ± 0.83
Mm.296901 Histocompatibility 2, Q region locus 7 (H2-Q7) 4.55 ± 2.49 4.58/- 10.22 ± 4.92 9.50 ± 0.76
Mm.296901 Histocompatibility 2, Q region locus 8 (H2-Q8) NE NE 4.45 ± 0.48 NE
Genes that are involved in the virus response and immune response were upregulated at 72 and 96 hr post infection concomitant with the virus 
appearance in the brain. Several inflammatory response and antigen presentation genes were upregulated and their expression increased with the 
progression of the disease. Values are fold changes in the gene expression in test samples over saline controls. Values are expressed as mean ± 
SEM. NE indicates not expressed or expression was lower than 1 fold (and/or did not meet the cut off criteria of 99% confidence interval, 150 
minimum intensity or 30 μm spot size) NE indicates not expressed and '-' indicates not expressed in biological replicates.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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observed at 96 hr post infection by PCR, where increases
in inflammation and neutrophil migration were also
observed.
Several apoptosis related genes were also upregu-
lated.Clusterin (Clu), an anti-apoptotic factor, activates
microglia to secrete neurotoxic agents [27]. Clu-activated
Table 4: Genes involved in apoptotic response in VEEV infected mice brain.
UniGene ID Functional Grouping (Gene) Upregulation (fold change) (Hours post infection)
24 48 72 96
Apoptosis
Mm.3336 RIKEN cDNA 1110007C09 gene (1110007C09Rik) 2.66 ± 1.63 3.68 ± 1.14 6.81 ± 4.35 5.22 ± 0.66
Mm.277585 amyloid beta (A4) precursor protein (App) 2.50 ± 0.48 2.54 ± 0.59 4.05 ± 1.20 2.87 ± 0.42
Mm.84073 Bcl2-associated athanogene 3 (Bag3) 2.63 ± 0.59 3.30 ± 0.43 4.61 ± 2.37 4.23 ± 0.18
Mm.29820 BCL2/adenovirus E1B 19kDa-interacting protein 3-like (Bnip3l) 1.96 ± 0.11 2.52 ± 0.04 3.88 ± 2.19 3.07 ± 0.14
Mm.290908 baculoviral IAP repeat-containing 6 (Birc6), mRNA. 1.94 ± 0.33 2.15 ± 0.22 2.54 ± 0.93 2.18 ± 0.04
Mm.283714 sialophorin (Spn), mRNA. 1.99 ± 0.14 2.50 ± 0.19 2.87 ± 1.63 2.25 ± 0.24
Mm.2381 amyloid beta (A4) precursor-like protein 1 (Aplp1), NE 1.90 ± 0.06 3.70 ± 1.15 2.27 ± 0.14
Mm.200608 Clusterin (Clu) NE 1.74 ± 0.13 4.03 ± 1.54 2.45 ± 0.37
Mm.136224 interferon induced with helicase C domain 1 (Ifih1) NE 3.59/- 5.21 ± 1.05 4.18 ± 0.31
Mm.4266 integral membrane protein 2B (Itm2b) NE 1.55 ± 0.20 2.43 ± 0.95 2.46 ± 0.54
Mm.2326 macrophage migration inhibitory factor (Mif) NE 1.08 ± 0.17 2.25 ± 0.53 2.06 ± 0.07
Mm.277518 Monocyte to macrophage differentiation-associated (Mmd) NE 0.59 ± 0.04 2.33 ± 0.45 1.64 ± 0.18
Mm.347546 Inositol 1,3,4-triphosphate 5/6 kinase NE 1.94 ± 0.02 0.95 ± 0.05 1.83 ± 0.02
Mm.285322 mitochondrial carrier homolog 1 (C. elegans) (Mtch1) NE 0.95 ± 0.01 2.08 ± 0.35 1.77 ± 0.23
Mm.687 Ras homolog gene family, member B (Rhob) NE 1.17 ± 0.03 2.48 ± 0.87 1.59 ± 0.15
Mm.379457 Valosin containing protein (Vcp) NE 1.68 ± 0.15 2.04 ± 0.77 1.80 ± 0.17
Mm.6826 Apoptosis-associated tyrosine kinase (Aatk) NE NE 1.65 ± 0.07 1.20 ± 0.43
Mm.223689 Bifunctional apoptosis regulator (Bfar) NE NE 1.83 ± 0.58 1.70 ± 0.08
Mm.130832 caspase recruitment domain family, member 14 (Card14) NE NE 3.23 ± 1.52 2.69 ± 0.08
Mm.29028 Death associated protein 3 (Dap3) NE NE 1.87 ± 0.14 0.96 ± 0.03
Mm.280594 Death effector domain-containing DNA binding protein 2 (Dedd2) NE NE 1.79 ± 0.66 1.92 ± 0.09
Mm.379461 eukaryotic translation initiation factor 5A (Eif5a) NE NE 2.61 ± 0.49 1.92 ± 0.14
Mm.342392 engulfment and cell motility 1, ced-12 homolog (C. elegans) (Elmo1), 
transcript variant 2
NE NE 1.74 ± 0.21 1.41 ± 0.08
Mm.39760 Fas apoptotic inhibitory molecule 2 (Faim2) NE NE 2.85 ± 1.23 2.44 ± 0.12
Mm.281298 growth arrest and DNA-damage-inducible 45 gamma (Gadd45g) NE NE 3.16 ± 0.21 2.12 ± 0.05
Mm.15510 granzyme A (Gzma) NE NE 1.27 ± 0.41 1.94 ± 0.26
Mm.2720 Mitogen activated protein kinase 8 interacting protein 1 (Mapk8ip1) NE NE 2.25 ± 0.75 1.16 ± 0.19
Mm.1639 Myeloid cell leukemia sequence 1 (Mcl1) NE NE 1.83 ± 0.18 1.56 ± 0.09
Mm.204876 nucleolar protein 3 (apoptosis repressor with CARD domain) (Nol3) NE NE 2.02 ± 0.52 1.84 ± 0.09
Mm.24163 PYD and CARD domain containing (Pycard) NE NE 1.82 ± 0.17 1.38 ± 0.18
Mm.276325 superoxide dismutase 1, soluble (Sod1) NE NE 1.74 ± 0.22 1.54 ± 0.24
Mm.200792 tumor necrosis factor receptor superfamily, member 21 (Tnfrsf21) NE NE 2.37 ± 0.84 1.40 ± 0.17
Mm.1894 CD1d1 antigen (Cd1d1) NE NE NE 1.56 ± 0.01
Mm.217764 phosphoglucomutase 2 (Pgm2)/Itgb3bp NE NE NE 1.63 ± 0.11
Mm.312628 Serine (or cysteine) proteinase inhibitor, clade A, member 3G 
(Serpina3g)
NE NE NE 2.83 ± 0.18
Mm.218473 tumor differentially expressed 1 (Tde1)/Serinc3 NE NE NE 1.94 ± 0.01
Mm.338613 forkhead box O3a (Foxo3a) 1.92 ± 0.17 NE 2.26 ± 1.08 1.57 ± 0.03
Mm.22216 TSC22 domain family 3 (Tcs22d3) NE 1.63 ± 0.20 NE NE
Mm.1360 growth arrest and DNA-damage-inducible 45 beta (Gadd45b) NE 2.00 ± 0.33 NE 1.85 ± 0.03
Mm.329277 ubiquitin specific peptidase 14 (Usp14)/Thoc1 NE 1.90 ± 0.21 NE 2.02 ± 0.18
Mm.347406 CCAAT/enhancer binding protein (C/EBP), beta (Cebpb) NE NE 2.01 ± 0.17 NE
Mm.150 Fc receptor, IgG, high affinity 1(Fcgr1) NE NE 2.26 ± 0.26 NE
Mm.292100 fibrinogen-like protein 2 (Fgl2) NE NE 1.90 ± 0.27 NE
Mm.368515 myc-like oncogene, s-myc protein (Mycs) NE NE 3.11 ± 0.05 NE
Genes that are modulated in the apoptotic response were upregulated at 72 and 96 hr post infection concomitant with the virus appearance in the 
brain. Values are fold changes in the gene expression in test samples over saline controls. Values are expressed as mean ± SEM. NE indicates not 
expressed or expression was lower than 1 fold (and/or didn't meet the cut off criteria of 99% confidence interval, 150 minimum intensity or 30 μm 
spot size) and (-) indicates not expressed in biological replicates.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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microglia showed increased MHC class II expression,
secreted reactive nitrogen intermediates and TNF-α [27].
VEEV infection of the brain also results in the activation of
microglia [11,17] and thus Clu may contribute to the glio-
sis observed in VEEV pathogenesis. The caspase recruit-
ment domain (CARD) is a protein-binding module that
mediates the assembly of CARD-containing proteins into
apoptosis and NFκB signaling complexes [28]. CARD14,
a membrane-associated guanylate kinase (MAGUK) fam-
ily member containing CARD has been implicated in the
antigen-specific signaling by the TCR complex via BCL10-
mediated NFκB activation [29]. In our study, CARD14
upregulation was concomitant with the increased inflam-
mation and enhancement in apoptotic neurons. CARD14
may be involved in the VEEV antigen-initiated signaling
in lymphocytes or glial cells and/or in the apoptotic path-
ways in neurons. Faim2 inhibits Fas-mediated apoptosis
and helps in protecting foreign antigen-specific B cells
during potentially hazardous interactions with FasL-bear-
ing T cells [30]. Faim2 was upregulated following VEEV
infection and may be involved in the activation and sur-
vival of immune cells in the brain. The paradoxical find-
ings on the over-expression of pro-apoptotic CARD 14
and anti-apoptotic Faim2 may be due to their expression
by different cell population in the brain.
Conclusion
Our results show a complex immune response to VEEV
infection. Several pathways seem to interact for the final
outcome of the disease. Thus, suppression of the inflam-
matory response and enhancement of the antiviral path-
ways may help in reducing the severity of the disease. We
have identified several genes e.g., chemokines, Oas1b,
Fcerg1, Mif and Clu which may provide potential targets
for therapy against VEEV infection in the future.
Methods
Animals
Six to ten week old male CD-1 mice were obtained from
Charles River Laboratories, Wilmington, MA. Mice were
housed in micro isolator cages and were provided food
and water ad libitum. A 12 hr light/dark cycle was main-
tained. All experiments were carried out in a bio-safety
level 3 (BSL-3) facility and in accordance with the Guide
for the Care and Use of Laboratory Animals (Committee
on Care And Use of Laboratory Animals of The Institute of
Laboratory Animal Resources, National Research Council,
NIH Publication No. 86–23, revised 1996).
Virus and Challenge Procedure
A full length cDNA clone of VEEV subtype IA/B, V3000 [5]
was used in the present study. Stock virus suspension was
diluted in 1× Dulbecco's Phosphate Buffered Saline
(DPBS) (Gibco BRL, Invitrogen Corporation Carlsbad,
CA) supplemented with 0.1% fetal bovine serum (FBS) to
1,000 plaque forming units (pfu)/25 μl. Mice were anes-
thetized lightly using inhalation anesthesia, isoflurane
and 1000 pfu of V3000 in 25 μl volume was injected in
the left rear footpad. Control animals were injected with
25 μl of 1× DPBS supplemented with 0.1% FBS.
Histopathology and Immunohistochemistry (IHC) for 
VEEV antigen
Two animals from each group (n = 10) were anesthetized
using isoflurane and sacrificed at 24, 48, 72 and 96 hr post
infection (pi), control mice were sacrificed at 96 hr pi.
Brains were collected and the right brain hemisphere was
fixed in 10% buffered neutral formalin (BNF) for 3–4
weeks. The left brain hemisphere was snap frozen at -
80°C. Tissues were then transferred into fresh BNF, rou-
tinely processed, and embedded in paraffin sections.
Immunostaining was performed using rabbit polyclonal
antiserum raised against VEEV (kindly provided by Cindy
Rossi and Dr George Ludwig, USAMRIID) by an indirect
Confirmation of selected gene expression by RT-PCR Figure 4
Confirmation of selected gene expression by RT-
PCR. (a) RT-PCR was performed for Oas1b, Fcre1g, Clu and 
Mif genes. Expression was normalized with housekeeping 
gene GAPDH. Lane 1: Negative control, Lane 2: uninfected 
saline control, Lane 3: 24 hr, Lane 4: 48 hr, Lane 5: 72 hr, 
Lane 6: 96 hr post infection. (b) Quantitative estimation was 
done by densitometry analysis of PCR product using Scion 
Image Analysis Software (Scion Corporation, Frederick, Mar-
yland 21701). Values were normalized to the corresponding 
values of the house keeping genes for individual samples. Val-
ues are expressed as mean ± SEM. * p ≤ 0.05 compared to 
uninfected control.BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
Page 10 of 12
(page number not for citation purposes)
avidin-biotin-immunoperoxidase technique (Vectastain
ABC Elite, Vector laboratories, Burlingame, CA) as
described before [31]. Briefly, sections were placed on
poly-L-lysine coated slides, deparaffinized and hydrated.
Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in methanol for 10 min. Non-specific
staining was blocked with 2.5% normal horse serum. Sec-
tions were incubated overnight with rabbit polyclonal
antiserum against VEE virus (1:10000) at 4°C. To ascer-
tain that the reaction of antibody was specific, sections
from each test were incubated with normal serum IgG sep-
arately. Slides were washed with phosphate-buffered
saline (PBS). Biotinylated secondary antibody IgG (H+L)
was added and incubated for 30 min. Sections were incu-
bated with streptaavidin-peroxidase complex for 10 min
and stained with diaminobenzidine (DAB) (Peroxidase
substrate kit DAB, Vector laboratories, Burlingame, CA),
counter stain used was Harris hematoxylin.
Isolation of total RNA
Frozen brain tissues were minced over ice and transferred
to 1.5 ml microfuge tubes. Total RNA was extracted using
TriZol kit (Invitrogen life technologies, Carlsbad, CA) and
quantitated spectrophotometrically using Beckman
DU640 Spectrophotometer (Beckman instruments Inc.,
Columbia, MD, USA). RNA quality was determined elec-
trophoretically on 1% agarose formaldehyde gel.
Microarray studies
High quality oligonucleotide glass arrays were produced
containing a total of 16,463 seventy-mer oligonucleotides
chosen from 750 bases of the 3' end of each ORF (open
reading frame) (Operon Inc. Valencia, CA). These 16,463
oligonucleotides represent 15,000 genes. The high quality
microarrays were produced in house (at CBER microarray
laboratory) by spotting 70-mer oligonucleotides on poly-
L-lysine coated glass slides by Gene Machines robotics
(Omnigrid, San Carlos, CA). The quality of printed arrays
was confirmed as described [32]. Only high quality arrays
that passed our quality control tests were used for these
experiments. We have followed the MIAME (minimum
information about a microarray experiment) guidelines
for the presentation of our data [33]. Microarray was per-
formed as described earlier [34]. Various steps involved in
the microarray are as follows:
i) Probe preparation: Labeled cDNA probes were pro-
duced as described [35,36]. Briefly, 5 μg of total RNA was
dissolved in 12 μl of DEPC water and incubated at 70°C
for 5 minutes along with 1 μl of aminoallyl-oligo dT (5'
amino-modified) primer and quickly chilled for 3 min-
utes. Then, 2 μl 10× first strand buffer, 1.5 μl Stratascript
RT enzyme (Stratagene, La Jolla, CA), 1.5 μl 20× ami-
noallyl dUTP (mixture of 100 mM dATP, dGTP, dCTP,
dTTP from Invitrogen, Carlsbad, CA and 50 mM ami-
noallyl dUTP from Ambion, Austin, TX) and 2 μl of 0.1 M
dithiothreitol (DTT, Invitrogen, Carlsbad, CA) were
added and incubated for 90 minutes at 42°C. After incu-
bation, volume of the reaction mixture was raised to 60 μl
with 40 μl of DEPC water.
cDNA was purified by MinElute column (Qiagen, Valen-
cia, CA). 300 μl of binding buffer PB was added to the
coupled cDNA and mixed thoroughly. The mixture was
applied to the MinElute column, and centrifuged for 1
min at max speed. After discharging the flow-through, 600
μl of washing buffer PE was added to the column, and
centrifuged for 1 min at max speed. The flow-through was
discharged and the washing repeated. The columns were
then placed into a fresh eppendorf tube and 10 μl elution
buffer added to the center of the membrane, incubated for
1 min at room temperature, centrifuged for 1 min at max
speed and probes were collected. Finally, 3 μl of 2× cou-
pling buffer (1 M NaHCO3, pH 9.0) and 5 μl Cy3 and 5
μl Cy5 (Amersham Biosciences, UK) dye mixed into
eluted buffers derived from both saline and VEE infected
samples respectively and incubated at room temperature
in dark for 90 minutes. Saline control probes were labeled
with Cy3 and probe from VEEV infected samples were
labeled with Cy5. After incubation, the volume was raised
to 60 μl by DEPC water and then cDNA was purified by
MinElute column and eluted with 13 μl elution buffer by
centrifugation.
ii) Hybridization: For hybridization, 36 μl hybridization
mixture [26 μl cDNA mixture, 1 μl (10 μg) COT-1 DNA, 1
μl (8–10 μg) poly(dA), 1 μl yeast tRNA (4 μg), 6 μl 20×
SSC and 1 μl 10% SDS] was pre-heated at 100°C for 2
minutes and cooled for 1 minute. Total volume of probe
was added on the array and covered with cover slip (22
mm × 40 mm). Slides were placed in hybridization cham-
ber (Genemachines) and 20 μl water was added to far end
of slide (to maintain humidity), and incubated overnight
(10–16 hr) at 65°C. Slides were then washed for 2 min-
utes each into 2× SSC, 1× SSC and 0.1× SSC and spin-
dried.
iii) Data filtration, normalization, and analysis: Microar-
ray slides were scanned in both Cy3 (532 nm) and Cy5
(635 nm) channels using Axon GenePix 4000B scanner
(Axon Instruments, Inc., Foster City, CA) with a 10-
micron resolution. Scanned microarray images were
exported as TIFF files to GenePix Pro 5.1 software for
image analysis. The raw images were collected at 16-bit/
pixel resolutions with 0 to 65,535 count dynamic range.
The area surrounding each spot image was used to calcu-
late a local background and subtracted from each spot
before Cy5:Cy3 ratio calculation. The average of the
resulting total Cy3 and Cy5 signal gave a ratio that was
used to normalize the signals. Each microarray experi-BMC Genomics 2008, 9:289 http://www.biomedcentral.com/1471-2164/9/289
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ment was globally normalized to make the median value
of the log2-ratio equal to zero. The normalization process
corrects for dye bias, PMT (Photo multiplier tube) voltage
imbalance, and variations between channels in the
amounts of the labeled cDNA probes hybridized. The data
files representing the differentially expressed genes were
then created.
For advanced data analysis, data files (in gpr format) and
image (in jpeg format) were imported into mAdb (micro-
array database, Center for Information Technology,
National Cancer Institute, Bethesda, MD, USA), and nor-
malized by software tools provided by National Institutes
Health, Center for Information Technology. Spots with
≥1.5 fold higher expression with at least 150-fluorescence
intensity in either channel or 30 μm spot size were consid-
ered as good quality spots for analysis with additional fil-
tration. These advanced filters prevented the potential
effect of the poor quality spots in data analysis. All VEEV
infected samples from four different time points were
hybridized in duplicates (biological replicate). The data
were further analyzed by Gene Ontology for Functional
Analysis (GOFFA) Library of Arraytrack software [36].
Reverse Transcription (RT) and Polymerase Chain 
Reaction (PCR)
cDNA was synthesized using the Superscript first strand
synthesis system for RT-PCR kit (Invitrogen Inc. Carlsbad,
CA). Briefly, primer mix (1ugRNA, dNTP, oligo dts) was
incubated at 65°C for 5 min then mixed with reaction
mixture (10× PCR buffer, 25 mM MgCl2, 0.1 M DTT,
RNase inhibitor) and incubated at 42°C for 2 min. cDNA
synthesis was done using RT enzyme (SSII) at 42°C for 50
min. The reaction was stopped by incubating at 70°C for
15 min. Residual RNA was digested by E. coli RNase H at
37°C for 20 min and samples were stored at -20°C. PCR
was performed to validate few of the genes that were iden-
tified in the microarray. Primers and conditions used for
the different genes are as follows. Clu: forward primer
(BC075668.1: 36–52) 5'GACTCCAGATTCCAAGG'3,
reverse primer (BC075668.1: 419-401) 5'GGTATGCT-
TCAGGCAGGGC'3 (95°C/30 s, 50°C/45 s, 72°C/45 s: 20
cycles),; Oas1b: forward primer (BC012877.1: 250–266)
5'GCTCAAGGGCAGGTCAG'3, reverse primer
(BC012877.1: 652-635) 5'GGTTGGGCGACAGTTCAG'3
(95°C/30 s, 52°C/45 s, 72°C/45 s: 22 cycles); Mif: for-
ward primer (NM_010798.2: 19–37) 5'CTGGCTTGGGT-
CACACCGC'3, reverse primer (NM_010798.2: 383-367)
5'CGTAATAGTTGATGTAG'3 (95°C/30 s, 45°C/45 s,
72°C/45 s: 23 cycles); Fcer1g: forward primer
(NM_010185.4: 207–225) 5'TATGGTATTGTCCTTAC'3,
reverse primer (NM_010185.4: 429–412) 5'CCAAGAG-
GGCTCGGAGAG'3 (95°C/30 s, 49°C/45 s, 72°C/45 s: 23
cycles); CxCl11 primer mix was purchased from Superar-
ray Bioscience Corporation, Frederic MD, RefSeq Acces-
sion # NM_019494.1, position 693–713 (95°C/30 s,
55°C/45 s, 72°C/45 s: 23 cycles); GAPDH: forward
primer 5'CCATCACCATCTTCCAGGAGCGAG'3, reverse
primer 5'CACAGTCTTCTGGGTGGCAGTGAT'3 (95°C/30
s, 52°C/45 s, 72°C/45 s: 25 cycles). PCR products were
visualized by electrophoreses over 1.2% agarose gel and
staining with ethidium bromide. Specific amplification
was determined by comparing the product size on gel rel-
ative to known DNA molecular weight marker. Further
PCR products were sequenced and checked for specific
amplification by blasting the sequence in the NCBI
genome database. Briefly, PCR products were pooled from
72 and 96 hr for each sample and purified using spin
QIAprep Spin Miniprep kit (Qiagen Inc. USA, Valencia,
CA). Sequencing reaction was done using BigDye Version
2.1(Applied Biosystems, Foster City, CA). Product was
then purified using Performa® DTR Gel Filtration Car-
tridges (Edge BioSystems, Gaithersburg, MD). Sequencing
was done in in-house facility on DNA Sequencer 3100
(Applied Biosystems, Foster City, CA).
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